Cashu
Overview of Avalo Therapeutics: Key Developments and Market Insights
4 months ago
Stocks
Health Care
avtx
Avalo Therapeutics
NASDAQ: AVTX
-0.61 (-3.90%)
15.03
USD
At close at Jan 16, 21:40 UTC
Overview
Loading chart...
Key Stats
Market Cap
198.07M
Dividend Yield
0.00%
P/E Ratio
-1.98
EPS
-31.72
Revenue
441.00K
Avg. Volume
307.73K
About
What does AVTX do?
Avalo Therapeutics, a clinical-stage biotechnology company headquartered in Rockville, Maryland, focuses on immune dysregulation therapies, with key assets including AVTX-009, quisovalimab, and AVTX-008. The company went public on November 13, 2015, and employs 19 people.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.